MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

PUBLISH ONLY Journal of Thoracic Oncology

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Long-Term Outcomes of En Bloc Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet and Spine Elie Fadel, MD, Gilles Missenard, MD, Charles.

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Surgical treatment of non-small cell lung cancer 1 cm or less in diameter Daniel L Miller, MD, Charles M Rowland, MS, Claude Deschamps, MD, Mark S Allen,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

PUBLISH ONLY Journal of Thoracic Oncology

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Erratum Journal of Thoracic Oncology

PD5-2-5: Local therapy of primary diseae improves survival in non-small cell lung cancer metastatic to a single organ - a lesson from brain metastases

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

PD5-1-7: Time trends in nodal CT volume and nodal motion during radiotherapy for patients with stage III non-small cell lung cancer Geert Bosmans, Angela.

P3-252: Limited surgery for elderly patients with non-small cell lung cancer who have high risk for lobectomy: Comparison of the short- and the long-term.

P3-255: Tumor size as a prognostic factor for the survival of surgically treated stage Ia non-small cell carcinoma Gustavo A. Lyons, Silvia Quadrelli,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Subclavian Artery Resection and Reconstruction for Thoracic Inlet Cancer: 25 Years of Experience Benoit Lahon, MD, Olaf Mercier, MD, PhD, Elie Fadel,

MTP13-01: Indications and limitations of bronchoscopy

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Journal of Thoracic Oncology

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

In This Issue Journal of Thoracic Oncology

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

IASLC 6th Latin American Conference on Lung Cancer

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

The Development of an International Registry

Journal of Thoracic Oncology

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Mark A. Socinski, MD Journal of Thoracic Oncology

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a radical resection is performed Philippe G. Dartevelle, Bedrettin Yildizeli, Elie Fadel, Sacha Mussot Journal of Thoracic Oncology Volume 2, Issue 8, Pages S285-S286 (August 2007) DOI: 10.1097/01.JTO.0000283060.34074.49 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Actuarial survival for patients with T4 Non-small Cell Lung Cancer undergoing resection, including the operative deaths. The estimated 5-, and 10-year survivals were 38.4%, and 26%, respectively. A total of 73 patients were alive at 5 years, and 25 at 10 years. Journal of Thoracic Oncology 2007 2, S285-S286DOI: (10.1097/01.JTO.0000283060.34074.49) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions